Lipoprotein apheresis is the most effective means of lipid-lowering therapy. However, it’s a semi-invasive, time consuming, and chronic therapy with variable adherence. There are still no specific ... guideline…
investigate the effect of leukocyte filtration on the P-selectin (CD62P) surface expression of apheresis platelets during the retention period. Ten bags of apheresis platelets stored ... bags of apheresis platelets…
density lipoprotein (LDL) apheresis is utilized in clinical practice with patients suffering from lipid disorders with a high and very high cardiovascular risk. One treatment allows to reduce the concentration…
this study, the clinical transfusion effects of fresh and cryopreserved apheresis leukocyte-reduced Platelets (PLTs) were examined. In total, 102 patients admitted to our hospital between August 2012 and August…
lowered from the blood plasma in a few hours by means of a specific apheresis with a selective adsorber. CRP apheresis was first used in patients after an acute heart ... attack (AMI). The apheresis takes place 2 or 3…
lipid-lowering drugs as well as mechanical removal of plasma LDL by means of apheresis. Statins are the most prescribed drugs for HoFH. Frequently, Statins alone do not lower LDLcholesterol ... Fenofibratemay enhance…
This was a retrospective single center study of all adverse events related to all apheresis donations between August 2018 and April 2019. All donors underwent complete hemogram and TTI testing ... presyncope/syncope…
practice, quantification of peripheral blood CD34+ cells is a method of choice to calculate apheresis yield. Nevertheless, other predictive factors have been evaluated. The objective of this study ... investigate the…
advantages of the Therapeutic Apheresis (TA) with membrane modules, which became available since the mid-1970s, are a complete separation of the blood cells from the plasma. Autoimmune diseases have
Context Severe hypertriglyceridemia is a known cause of acute pancreatitis, and apheresis treatment, most commonly plasmapheresis, has been used to treat patients with drug refractory hypetriglyceridemia for more than…
chronic rejection, medicines with many side complications are used. Methods: At the same time, apheresis therapy methods aimed at removing antibodies from the body have not received enough proper ... this work was to…
much stronger effect than that of low density lipoprotein bound cholesterol (LDL)-apheresis, which is recognized as the most effective therapy for hyperlipidemia. I experienced a rare case in which ... ezetimibe…
much stronger effect than that of low density lipoprotein bound cholesterol (LDL)-apheresis, which is recognized as the most effective therapy for hyperlipidemia. I experienced a rare case in which ... ezetimibe…
advantages of the Therapeutic Apheresis (TA) with membrane modules, which became available since the mid-1970s, are a complete separation of the blood cells from the plasma. Autoimmune diseases have
focused on the removal of autoantibodies and the maintenance of a healthy immune system. Apheresis is a promising therapy strategy from a theoretical aspect since it works by eliminating pathogenic
elimination of autoantibodies and a favourable immune system regulation. From a theoretical standpoint, apheresis is a promising treatment approach since it works by removing pathogenic components rather than giving…
those CD34+ subpopulation express more TNFR1. A little increase in TNFR2 expression after apheresis indicated successful process cell accumulation and especially cell accumulation with better quality. The cells with high
active thrombophilia status and with respect to very thin coronary arteries a weekly lipoprotein apheresis treatment (LA) was initiated. Before LA was initiated the patient was getting pregnant twice
Republic Research Center of Transfusion, platelet production is mainly supported (about 99%) by apheresis. However, apheresis donations have limitations caused by donor eligibility due to both donor preferences and…
hemolysis, although very rare, may be encountered in case of transfusion of ABO-incompatible apheresis (single donor) platelets. Case Report: A 61-year-old female, blood group A, with acute ... required platelet…
density lipoprotein apheresis device (Rheocarna®; Kaneka Corporation, Osaka, Japan) was developed in Japan for treating Chronic Limb T hreatening Ischemia (CLTI) with refractory ulcers (Rutherford classification score
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.